Dr. Reddy's Laboratories Stock Analysis

Dr. Reddy's Laboratories Limited is a leading integrated pharmaceutical company operating worldwide. It manufactures and markets prescription and over-the-counter pharmaceutical products, active pharmaceutical ingredients, and intermediates. The company also engages in contract research services, biologics business, and digital healthcare services.

Overview

Dr. Reddy's Laboratories operates through the Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. It offers products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, and respiratory.

Key Financial Statistics

• Current Price: INR 6943.3
• Market Cap: INR 1,156,580,245,504
• Dividend Rate: 40.0
• Trailing PE: 20.84
• Forward PE: 20.24
• Enterprise Value: INR 1,092,423,581,696

Company Officers

Dr. Reddy's Laboratories is led by a team of experienced and qualified company officers including the Chairman, Co-Chairman, CEO, CFO, and other key executives.

Key Ratios and Margins

• Profit Margins: 19.26%
• Return on Assets: 10.93%
• Return on Equity: 20.59%
• Operating Margins: 23.39%
• Debt to Equity: 10.41

Analyst Recommendations

The stock has a target mean price of INR 6172.76 with a recommendation mean of 2.9 (Hold). There are 34 analyst opinions available for the stock.

Conclusion

Dr. Reddy's Laboratories Limited is a well-established pharmaceutical company with a strong global presence and a diverse product portfolio. The company's financial indicators and analyst recommendations suggest a stable investment opportunity.